GSTM1 and chronic kidney disease: In this NMA, Hb response was evaluated across 45 RCTs comparing six HIF-PHIs—roxadustat, daprodustat, vadadustat, molidustat, enarodustat, and desidustat—with ESAs or placebo in over 32,000 CKD patients.